GEDEON RICHTER IRELAND LIMITED

Gedeon Richter Ireland Limited is the Irish arm of the internationally-operating Gedeon Richter Group, a pharmaceutical organisation whose mission is "Health is our mission". The company focuses on delivering high-added-value therapies to patients worldwide, investing heavily in research and development to bring new medicines from discovery through to market - a process that can span up to 15 years and requires substantial financial and scientific commitment.

The portfolio spans several therapeutic areas, including neuropsychiatry, biotechnology and women's healthcare. Notable recent achievements include FDA approval for the denosumab biosimilars Enoby™ and Xtrenbo™ (referencing Prolia and Xgeva) in partnership with Hikma, and the ten-year anniversary of the antipsychotic cariprazine, a breakthrough treatment for mental health disorders. Gedeon Richter Ireland also highlights its stable, attractive workplace, underscoring a corporate culture that values both innovation and employee wellbeing. Through these efforts, the company aims to improve patient outcomes across Ireland and the broader global market.